ESC 2025: Potássio e Arritmias, Apixabana no TEV, B-bloqueadores Após IAM - Fofoca Científica #7

In this edition of Fofoca Científica, we'll be reviewing some of our favorite studies presented at the 2025 European Society of Cardiology (ESC) Congress. Aline Campos and Lucca Cirillo will discuss four new studies in cardiology: POTCAST (potassium targets in patients at high risk of arrhythmias), HI-PRO (prolonged apixaban after provoked venous thromboembolism), REBOOT-CNIC, and BETAMI-DANBLOCK (beta-blocker therapy after acute myocardial infarction). Want to delve deeper into these studies and what else happened at the 2025 ESC Congress? Check out our full TdC Guide topic at: https://www.tadeclinicagem.com.br/gui... POTCAST (potassium goals in patients at high risk of arrhythmias): https://pubmed.ncbi.nlm.nih.gov/40879... HI-PRO (long-term apixaban after provoked venous thromboembolism): https://pubmed.ncbi.nlm.nih.gov/40888... REBOOT-CNIC and BETAMI-DANBLOCK (beta-blocker after acute myocardial infarction): https://pubmed.ncbi.nlm.nih.gov/40888... and https://pubmed.ncbi.nlm.nih.gov/40888... 🚨 www.tadeclinicagem.com.br/guia - Get the TdC Guide with a 7-day free trial 🚨 🔴 Join over 5,000 subscribers. Subscribe to the Guide, save time, and stay up-to-date effortlessly. Like and follow TdC on other social media: 🩺 Instagram: @Tadeclinicagem 🩺 TikTok: https://www.tiktok.com/amp/tag/tadecl... Learn about Clinical Medicine in an educational, fun, and evidence-based way! Share TdC with your friends! ⚠️ ATTENTION: This content is intended exclusively for medical education purposes and does not replace the individualized evaluation of a healthcare professional. The information presented here should not be interpreted as medical advice, prescription, or treatment recommendation. If you have any questions about your health or treatments, always consult a doctor or qualified professional.